[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE035985T2 - HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma - Google Patents

HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma

Info

Publication number
HUE035985T2
HUE035985T2 HUE10181268A HUE10181268A HUE035985T2 HU E035985 T2 HUE035985 T2 HU E035985T2 HU E10181268 A HUE10181268 A HU E10181268A HU E10181268 A HUE10181268 A HU E10181268A HU E035985 T2 HUE035985 T2 HU E035985T2
Authority
HU
Hungary
Prior art keywords
dosage form
hiv protease
pharmaceutical dosage
protease inhibitor
solid
Prior art date
Application number
HUE10181268A
Other languages
English (en)
Inventor
Joerg Rosenberg
Ulrich Reinhold
Bernd Liepold
Gunther Berndl
Laman Alani
Soumojeet Ghosh
Joerg Breitenbach
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE035985(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HUE035985T2 publication Critical patent/HUE035985T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE10181268A 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma HUE035985T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/650,178 US20050048112A1 (en) 2003-08-28 2003-08-28 Solid pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
HUE035985T2 true HUE035985T2 (hu) 2018-06-28

Family

ID=34217089

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE15169378A HUE038792T2 (hu) 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma
HUE10181264A HUE031153T2 (hu) 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma
HUE10181268A HUE035985T2 (hu) 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE15169378A HUE038792T2 (hu) 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma
HUE10181264A HUE031153T2 (hu) 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma

Country Status (31)

Country Link
US (1) US20050048112A1 (hu)
EP (6) EP2942051B1 (hu)
JP (6) JP4815348B2 (hu)
KR (5) KR101132602B1 (hu)
CN (5) CN102764244A (hu)
AT (1) ATE516017T1 (hu)
AU (3) AU2004283087C1 (hu)
CA (2) CA2536638C (hu)
CR (3) CR8256A (hu)
CY (5) CY1111981T1 (hu)
DK (5) DK2258345T3 (hu)
EA (4) EA020992B1 (hu)
EC (1) ECSP066397A (hu)
ES (5) ES2608720T3 (hu)
HK (4) HK1094766A1 (hu)
HR (1) HRP20110555T1 (hu)
HU (3) HUE038792T2 (hu)
IL (3) IL173939A (hu)
ME (2) MEP17608A (hu)
MX (2) MX358033B (hu)
NO (3) NO330282B1 (hu)
NZ (2) NZ579622A (hu)
PL (5) PL1663183T3 (hu)
PT (5) PT2258344E (hu)
RS (2) RS59969B1 (hu)
SG (3) SG145690A1 (hu)
SI (5) SI2258345T1 (hu)
TW (1) TWI342221B (hu)
UA (1) UA85564C2 (hu)
WO (1) WO2005039551A2 (hu)
ZA (3) ZA200801362B (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
ATE482690T1 (de) * 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
JP5231242B2 (ja) * 2005-12-14 2013-07-10 シプラ・リミテッド ヌクレオチド及びヌクレオシド系逆転写酵素阻害剤（テノホビル及びラミブジン）を剤形の異なる部分に含む医薬組合せ
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
TW200815033A (en) * 2006-08-10 2008-04-01 Cipla Ltd Antiretroviral solid oral composition
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
CN103435570B (zh) 2007-02-23 2015-06-10 吉里德科学公司 治疗剂的药代动力学特性调节剂
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
EP2257279B1 (en) * 2008-02-28 2016-08-17 AbbVie Inc. Preparation of tablets
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
ES2598178T5 (es) * 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
EP2391350A1 (en) 2008-12-18 2011-12-07 Ranbaxy Laboratories Limited Atazanavir formulations
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
EP2279728A1 (en) 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2829186A1 (en) * 2011-03-07 2012-09-13 Bandi Parthasaradhi Reddy Amorphous form of lopinavir and ritonavir mixture
US9096556B2 (en) 2011-05-27 2015-08-04 Hetero Research Foundation Amorphous ritonavir co-precipitated
CA2844827A1 (en) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
EP2564832A1 (en) 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
WO2013131646A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
HUE027829T2 (hu) 2012-03-07 2016-11-28 Ratiopharm Gmbh Nem kristályos lopinavirt és kristályos ritonavirt tartalmazó dózisforma
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
WO2014048783A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
WO2014048782A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) * 2017-08-07 2019-02-07 SE Tylose, USA, Inc. Pharmaceutical composition in solid extruded form
US20190269662A1 (en) * 2018-03-02 2019-09-05 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
EP4255495A1 (en) 2020-12-03 2023-10-11 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) * 2022-03-17 2023-06-02 乐普制药科技有限公司 一种利托那韦固体分散体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5542206A (en) 1994-10-11 1996-08-06 Lisch; Albert Lure and tackle stacking container
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) * 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
ATE429224T1 (de) 1999-06-04 2009-05-15 Abbott Lab Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor
ATE286720T1 (de) 1999-11-12 2005-01-15 Abbott Lab Pharmazeutische formulierungen auf basis fester dispersionen
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
MXPA03011922A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen un dispersion solida de un farmaco ligeramente soluble en una matriz y plimero mejorador de solubilidad.
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
DE10213242A1 (de) 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations

Also Published As

Publication number Publication date
NO330282B1 (no) 2011-03-21
ATE516017T1 (de) 2011-07-15
HK1094766A1 (en) 2007-04-13
JP2016094433A (ja) 2016-05-26
PL2258345T3 (pl) 2017-03-31
SG10201507902UA (en) 2015-10-29
JP4815348B2 (ja) 2011-11-16
JP5395125B2 (ja) 2014-01-22
EP2258344A2 (en) 2010-12-08
ZA200801362B (en) 2009-03-25
EA020992B1 (ru) 2015-03-31
AU2010238573B2 (en) 2012-12-13
AU2007249115B2 (en) 2010-08-12
PL2258346T3 (pl) 2018-01-31
CR20120662A (es) 2013-03-13
CN101919858A (zh) 2010-12-22
NO334418B1 (no) 2014-03-03
KR101457967B1 (ko) 2014-11-07
CN102772380B (zh) 2015-08-19
PT2942051T (pt) 2018-04-23
EP2942051A1 (en) 2015-11-11
HK1217298A1 (zh) 2017-01-06
CN102764244A (zh) 2012-11-07
RS20060140A (en) 2008-09-29
EA033224B1 (ru) 2019-09-30
CN1901884B (zh) 2012-07-25
DK2258346T3 (da) 2017-11-13
ECSP066397A (es) 2006-08-30
KR20110122771A (ko) 2011-11-10
KR101132602B1 (ko) 2012-04-06
JP2013241460A (ja) 2013-12-05
ZA200801361B (en) 2011-11-30
HRP20110555T1 (hr) 2011-09-30
CY1111981T1 (el) 2015-11-04
EA200900292A1 (ru) 2009-06-30
EP2258345B1 (en) 2016-09-21
RS59969B1 (sr) 2020-03-31
KR20120054666A (ko) 2012-05-30
MXPA06002346A (es) 2006-05-19
HUE038792T2 (hu) 2018-11-28
CY1120138T1 (el) 2018-12-12
SI2258346T1 (sl) 2017-12-29
MEP17608A (en) 2010-06-10
CA2536638C (en) 2010-04-06
EP1663183B1 (en) 2011-07-13
UA85564C2 (ru) 2009-02-10
CY1113596T1 (el) 2016-06-22
EP2258345A2 (en) 2010-12-08
CA2689639C (en) 2014-06-10
ES2653762T3 (es) 2018-02-08
NZ579622A (en) 2011-01-28
KR101281994B1 (ko) 2013-07-04
EP3354261A1 (en) 2018-08-01
EP1663183A2 (en) 2006-06-07
EA011924B1 (ru) 2009-06-30
EP1663183B9 (en) 2012-06-13
HK1145969A1 (en) 2011-05-13
EA201890737A2 (ru) 2018-08-31
DK2942051T3 (en) 2018-05-07
PT2258344E (pt) 2013-02-18
PL2942051T3 (pl) 2018-07-31
SI2942051T1 (en) 2018-06-29
JP2011236232A (ja) 2011-11-24
DK1663183T3 (da) 2011-08-29
PT1663183E (pt) 2011-08-25
SI2258344T1 (sl) 2013-03-29
KR20150044031A (ko) 2015-04-23
CR8256A (es) 2008-01-11
EP2258346B1 (en) 2017-09-27
EP2942051B1 (en) 2018-01-17
KR101563222B1 (ko) 2015-10-26
PT2258346T (pt) 2017-10-24
WO2005039551A2 (en) 2005-05-06
AU2004283087C1 (en) 2008-04-24
JP2011126898A (ja) 2011-06-30
CA2536638A1 (en) 2005-05-06
IL254581A0 (en) 2017-11-30
JP2007504142A (ja) 2007-03-01
CR20120661A (es) 2013-03-13
MX358033B (es) 2018-08-02
SI1663183T1 (sl) 2011-09-30
TW200522979A (en) 2005-07-16
DK2258345T3 (en) 2017-01-16
RS20181262A1 (sr) 2019-02-28
CN105106104A (zh) 2015-12-02
CY1119651T1 (el) 2018-04-04
AU2007249115A1 (en) 2008-01-10
CN1901884A (zh) 2007-01-24
SI2258345T1 (sl) 2017-01-31
IL173939A0 (en) 2006-07-05
AU2010238573A1 (en) 2010-11-18
EP2258344B1 (en) 2012-11-14
NO335326B1 (no) 2014-11-10
NO20061342L (no) 2006-05-29
EA200600473A1 (ru) 2006-10-27
KR20140046078A (ko) 2014-04-17
AU2004283087A1 (en) 2005-05-06
ES2399810T3 (es) 2013-04-03
JP5498411B2 (ja) 2014-05-21
WO2005039551A3 (en) 2006-08-03
PL1663183T3 (pl) 2011-10-31
NZ545499A (en) 2009-11-27
AU2004283087B2 (en) 2007-09-20
EP2258346A2 (en) 2010-12-08
ES2367173T3 (es) 2011-10-31
CA2689639A1 (en) 2005-05-06
CN102772380A (zh) 2012-11-14
NO20100367L (no) 2006-05-29
EA201301045A1 (ru) 2014-05-30
RS57663B1 (sr) 2018-11-30
EA201890737A3 (ru) 2019-01-31
ME00130B (me) 2010-10-10
DK2258344T3 (da) 2013-01-02
ES2666390T3 (es) 2018-05-04
ES2608720T3 (es) 2017-04-12
PT2258345T (pt) 2017-01-20
NO20131743L (no) 2006-05-29
EP2258346A3 (en) 2011-01-19
TWI342221B (en) 2011-05-21
SG179401A1 (en) 2012-04-27
JP2018035163A (ja) 2018-03-08
CN101919858B (zh) 2013-10-30
ZA200601718B (en) 2009-11-25
KR20060121837A (ko) 2006-11-29
IL207260A (en) 2017-10-31
SG145690A1 (en) 2008-09-29
EP2258344A3 (en) 2011-01-19
CY1118505T1 (el) 2017-07-12
HK1257502A1 (zh) 2019-10-25
PL2258344T3 (pl) 2013-04-30
EP2258345A3 (en) 2011-01-19
HUE031153T2 (hu) 2017-07-28
US20050048112A1 (en) 2005-03-03
IL173939A (en) 2017-03-30
JP5903413B2 (ja) 2016-04-13

Similar Documents

Publication Publication Date Title
HK1257502A1 (zh) 一種包含hiv蛋白酶抑制劑固體分散體的固體藥物劑型